Nutlin analogs (MI-219 and MI-319) have shown an ability to inhibit MDM2, thus enhancing p53 expression in pancreatic cancer [322]; however, this will not occur in tumors with mutated p53. This evidence concerns the gene MDM2 and familial pancreatic carcinoma.